Compare WILC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | MYGN |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.6M | 444.2M |
| IPO Year | 2001 | 1996 |
| Metric | WILC | MYGN |
|---|---|---|
| Price | $36.07 | $3.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 3.0K | ★ 1.4M |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $15.30 | $3.75 |
| 52 Week High | $36.90 | $8.59 |
| Indicator | WILC | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 30.29 |
| Support Level | $26.29 | N/A |
| Resistance Level | N/A | $5.30 |
| Average True Range (ATR) | 1.27 | 0.28 |
| MACD | 0.25 | -0.12 |
| Stochastic Oscillator | 77.82 | 0.00 |
G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.